Develops stem cell preparations for regenerative therapies.
Jul 2026Revenue $0.00/yrExpenses $455K/yr
No trend
Figures by year
When will Vitaspring Biomedical be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jul 2026, revenue was $0.00 and expenses $455K.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jan 2026 | $0.00 | $385K | −$385K |
| Jan 2025 | $0.00 | $680K | −$680K |
| Jan 2024 | $0.00 | $1.12M | −$1.12M |
| Jan 2023 | $0.00 | $4.18M | −$4.18M |
| Jan 2022 | $5.61M | $4.49M | $1.13M |
| Jan 2021 | $248K | −$177K | $425K |
| Jan 2020 | $15.1K | $8.22K | $6.92K |
| Jan 2019 | $17.2K | $39.6K | −$22.4K |
| Jan 2018 | $16.2K | $22.6K | −$6.37K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.